PARIS, September 5, 2020 – The TIDES-ACS Randomized Controlled Trial results have been published end of July 2020 confirming the superior safety and sustained non-inferior efficacy of the Bio-Active Stent technology developed by Hexacath at 18 months follow up versus top drug-eluting stent.